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Abstract: Strongyloidiasis is a disease caused by soil transmitted helminths of the Strongyloides
genus. Currently, it is predominately described as a neglected tropical disease. However, this
description is misleading as it focuses on the geographical location of the disease and not the primary
consideration, which is the socioeconomic conditions and poor infrastructure found within endemic
regions. This classification may result in misdiagnosis and mistreatment by physicians, but more
importantly, it influences how the disease is fundamentally viewed. Strongyloidiasis must be first and
foremost considered as a disease of disadvantage, to ensure the correct strategies and control measures
are used to prevent infection. Changing how strongyloidiasis is perceived from a geographic and
clinical issue to an environmental health issue represents the first step in identifying appropriate
long term control measures. This includes emphasis on environmental health controls, such as
better infrastructure, sanitation and living conditions. This review explores the global prevalence
of strongyloidiasis in relation to its presence in subtropical, tropical and temperate climate zones
with mild and cold winters, but also explores the corresponding socioeconomic conditions of these
regions. The evidence shows that strongyloidiasis is primarily determined by the socioeconomic
status of the communities rather than geographic or climatic conditions. It demonstrates that
strongyloidiasis should no longer be referred to as a “tropical” disease but rather a disease of
disadvantage. This philosophical shift will promote the development of correct control strategies for
preventing this disease of disadvantage.
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1. Introduction
Strongyloidiasis is an underestimated disease caused by Strongyloides stercoralis and
Strongyloides fuelleborni, two species of soil-transmitted helminths of the genus Strongyloides [1,2]. While
Strongyloides fuelleborni is found sporadically in Africa and Papua New Guinea, Strongyloides stercoralis
is distributed worldwide and clinically important [1]. Rhabditiform larvae of S. stercoralis are excreted
in human feces, from where they develop into infected filariform larvae and can either repenetrate
the intestinal mucosa and remain in the human organism, or distribute environmentally to new
human hosts. A new host becomes infected with filariform larvae through intact skin penetration [3].
Strongyloidiasis can cause gastrointestinal symptoms, including abdominal pain, diarrhea, nausea and
vomiting, skin problems including pruritus and dermatitis or respiratory symptoms such as cough,
asthma and dyspnea [4–6]. Hyperinfection or disseminated strongyloidiasis can affect several organs,
leading to fatal outcomes [1,7]. Chronic asymptomatic strongyloidiasis is another significant concern,
as when coupled with immunosuppressive treatment, it has potential to develop into disseminated
infection [8].
Int. J. Environ. Res. Public Health 2016, 13, 517; doi:10.3390/ijerph13050517 www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2016, 13, 517 2 of 15
Currently, strongyloidiasis is predominately described as a neglected tropical disease, found in
tropical and subtropical areas (Southeast Asia, Africa, Central and South America) [9–14]. Whilst these
papers do not often include clear climate-area classifications, it seems inappropriate that the primary
disease descriptor focuses on geographic and climate conditions. Recent studies have included
countries of the temperate zones in the endemic areas for strongyloidiasis [15–19]. There are also cases
of strongyloidiasis in some parts of the same climatic zone but not in others [20–23]. This indicates
that climatic conditions are not the primary factors determining the disease presence. Few studies
mentioned low sanitation and socioeconomic status of communities as a risk factor for strongyloidiasis,
and those that did not examine socioeconomic and sanitation conditions in any depth [21,24].
This review explores the global prevalence of strongyloidiasis in relation to its presence in
subtropical, tropical and temperate climate zones with mild and cold winters, but also explores the
corresponding socioeconomic conditions of these regions. The review demonstrates that classifying
the disease as “tropical” is misleading and runs the risk that physicians in other countries may
not recognize this pathogen, resulting in misdiagnosis or mistreatment of the disease [15,25], but
most importantly it influences how the disease is fundamentally viewed. Correct classification and
perception of the strongyloidiasis is crucial, as it determines what strategies and control measures are
used to prevent the infection. Considering the disease as an environmental health issue than a clinical
issue based on geography would provoke a shift from drug administration to environmental health
controls. Clinical treatment of strongyloidiasis will not always be effective [13,26]. Anthelminthic drugs
do not prevent reinfection, and can also cause adverse health effects [27,28]. Additionally, resistance to
ivermectin (the primary drug used to treat strongyloidiasis) has already been found in Strongyloides spp.
infecting ruminants [29], suggesting that resistance to ivermectin in S. stercoralis is likely in the future.
Therefore, environmental health interventions represent a safer and more effective way of infection
treatment. It was more than twenty years ago that Grove [30] noted that controlling Strongyloides in
the environment is the most effective way to reduce infection. He pointed out that installation of
adequate waste disposal systems was the most effective method to control the nematode [30], although
this has not become the primary approach to addressing the disease. A major step towards reducing
Strongyloides infection is to change the global perception of strongyloidiasis as a neglected tropical
disease to recognition that it is primarily a disease of disadvantage and poor sanitation.
The aim of the current review was to assess the global prevalence of S. stercoralis to determine
prevalence in geographic locations or climate zones, and compare these with socioeconomic status
and poor infrastructure of the communities. The review demonstrates that strongyloidiasis should no
longer be referred to as a “tropical” disease but rather a disease of disadvantage. This philosophical
shift will promote the development of correct control strategies for preventing the disease.
Studies that collectively demonstrate the global distribution of S. stercoralis are presented in
Table 1. Studies were collated using the Google Scholar and PubMed journal databases and the key
words Strongyloides, S. stercoralis, strongyloidiasis, global, socioeconomic, status. Only studies from
1990–2016, written in English or Russian, with S. stercoralis prevalence percentage and details on
population studied were included in the review. Reference lists of the collected studies were also
examined and relevant articles have been reviewed.
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Table 1. Global Strongyloides stercoralis prevalence distribution.
NO. Most Likely InfectiveSource
Climate
Classification Population Studied SES
S. stercoralis
Prevalence (%)
Type of
Detection
Symptoms
Diagnosed Comments/Details Reference
1. East Africa Group A, C, B *
Immigrants (ě16) lived
in the refugee camps,
Melbourne community
health center and
clinic patients
Developing
economy 1 ** 11% (14/124) Serology
Fever (34%), Stomach
pain (30%), weight
loss (25%), and
diarrhea (13%)
Arrived to Australia,
Melbourne between
1997–2000
[4]
2. Cambodia Group A
Immigrants and
refugees (ě15),
Melbourne community
health center and
clinic patients
Developing
economy, 1 42% (97/230) Serology Not reported
Arrived to Australia,
Melbourne between
1974–2002
[4]
3. Laos Group A Immigrants (ě18) N/a 24% (22/93) Serology
75% (60/80) had
previously worms,
not known symptoms
Arrived to Australia,
Melbourne between
1980–1989
[31]
4.
Brazil (North, Northeast,
Midwest,
Southeast, South)
Group A, C General population Developingeconomy, 3
5.5%
21.7%
29.2%
Stool examination
Serology (IFAT)
Serology (ELISA)
Not reported Study conducted from1990 to 2009 [32]
5.
Mexico, Honduras,
Ethiopia, El Salvador,
Zambia, Argentina,
Congo, Cuba, Grenada,
Guatemala, India, Kenya,
Niger, Tanzania, Vietnam
Group A, C, B HIV-positiveimmigrants (ě17)
Developing
economy,
1,2,3
26% (33/128) Serology
Weight loss (53%),
diarrhea (48%),
fatigue (42%) and
abdominal
pain (36%).
[5]
6.
Africa, Central/South
America, Thailand,
India, UAE
Group A, B, C
HIV-positive
immigrants (ě18),
Italian hospital patients
Developing
economy,
1,2,3,4
11% (15/138) Serology
Skin problems
(16.7%),
gastrointestinal
symptoms (15%)
respiratory
problems (14%)
Study conducted from
2000 to 2009 [6]
7. Sub-Saharan Africa Group A, B, C
Immigrants, Royal
Melbourne Hospital,
Infectious disease
clinic patients
Developing
economy, 1
1.4% (2/145)
17.9% (32/179)
Stool examination
Serology Not reported
Study conducted from
2003 to 2006 [33]
8. China, southern Yunnanprovince *** Group A
Local rural
inhabitants, random
population sample
Developing
economy, 3 11.7% (21/180) Stool examination Not reported [17]
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NO. Most Likely InfectiveSource
Climate
Classification Population Studied SES
S. stercoralis
Prevalence (%)
Type of
Detection
Symptoms
Diagnosed Comments/Details Reference
9. Northern Ghana Group A
Local inhabitants,
random
population sample
Developing
economy, 2
11.6%
(2349/20250) Stool examination Not reported
Study conducted from
1995 to 1998 [34]
10. Northern Thailand Group A,C
Local inhabitants
excluding pregnant,
lactating or with
heart diseases
Developing
economy, 3
15.9%
(114/697) Stool examination
Study conducted from
April 2004 to
September 2004
[35]
11. Appalachia regions,Kentucky, US *** Group C,D
Local inhabitants,
clinic patients
Developed
economy, 4 1.9% (7/378) Serology Not reported All used outdoor toilet [21]
12. Spain, Barcelona Group C
Immigrants from
endemic areas,
few locals
Developed
economy, 4
17.7% (33/190)
46% (33/71)
Stool examination
Serology
Gastrointestinal
symptoms (64%),
dermatologic
symptoms (32%),
neurologic
symptoms (1%)
Study conducted from
2003 to 2012 [19]
13. Cambodia Group A Refugees Developingeconomy, 1
24.7% (40/162)
77.2%
(125/162)
Stool examination
Serology Not reported
Arrived to Canada
between 1982 and 1983 [36]
14. Spain, Valencia,Gandia *** Group C
Local farm workers,
random population
sample from the
tourist area
Developed
economy, 4 12.4 % (31/250)
Stool examination
(agar plate
culture)
Gastrointestinal
symptoms, skin
symptoms (no
predominance among
the infected group)
No information
obtained on travelling
details
[37]
15. Africa Group A, B, C Sudan refugees SomaliBantu refugees
Developing
economy, 1
46% (214/462)
23% (23/100) Serology Serology
Chronic abdominal
pain (not associated
with the infection
prevalence)
Resettled in the US in
previous 5 years [38]
16. Jamaica Group A
Clinical
strongyloidiasis
patients and controls
(neighboring
households)
Developing
economy, 3
8.2% (17/207)
30% (62/207)
Stool examination
Serology Not reported [39]
17. Far East andSoutheast Asia Group A, C, D
Former WWII Far East
prisoners, diagnosed
with strongyloidiasis
and controls
Developing
economy, 2,3 12% (248/2072)
Stool examination
and serology
Larva currens
rash (70%)
Study conducted from
1968 to 2002,
Liverpool, UK
[40]
18.
Sub-Saharan Africa,
Maghreb and
Latin America
Group A, B, C
Immigrants,
strongyloidiasis
patients
Developing
economy, 2,3
90.4%
(284/314)
22.9% (67/293)
Serology Stool
examination
Gastrointestinal
symptoms
(abdominal pain,
diarrhea, pruritus
Study conducted from
2004 to 2012,
Southern Spain
[18]
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Table 1. Cont.
NO. Most Likely InfectiveSource
Climate
Classification Population Studied SES
S. stercoralis
Prevalence (%)
Type of
Detection
Symptoms
Diagnosed Comments/Details Reference
19.
Africa, Eastern Europe,
Southeast Asia, South
America, the Caribbean,
and the Middle East
Group A, B, C Refugees
Developing
economy,
economy in
transition,
1,2,3
39% (45/119) Serology Asymptomatic Boston, Massachusetts [8]
20.
Southeast Asia
(Kampuchea,
Laos, Vietnam
Group A,C Immigrants, randompopulation sample
Developing
economy, 2
64.7%
(125/193)
25%
Serology Stool
examination Not reported Quebec, Canada [41]
21. Spain,Mediterranean coast, Group C
Strongyloidiasis
patients (ex and current
farm-workers and
family members),
local inhabitants
Developed
economy 4
0.9%
(152/16607)
Stool examination
(agar plate
culture)
Asymptomatic (77%);
Gastrointestinal
symptoms (11%);
cutaneous symptoms
(4%); respiratory
symptoms (1%);
mixture of all the
symptoms (7%)
Study conducted from
1990 to 1997, none
travelled to the
endemic areas
[42]
22. Northeastern Thailand Group A Rural and urbanpopulation
Developing
economy, 3
23.5%
(289.8/1233) Stool examination Not reported
Study conducted from
July to September 2002 [43]
23. Australia, Northernterritory *** Group A
Royal Darwin
Hospital patients
Developed
economy, 4 33% (68/205) Stool examination
Gastrointestinal
symptoms (72%) 12 month study [20]
24. India, Assam Group A,B, C
Local inhabitants,
random
population sample
Developing
economy, 2 8.5 % (17/198) Stool examination
Gastrointestinal,
respiratory and
cutaneous
symptoms (29%)
Locals are mostly
farm-workers [44]
25. Malaysia Group A Orang Asli community Developingeconomy, 3
0% (0/54)
31.5% (17/54)
5.6% (3/54)
Stool examination
Serology PCR Not reported [11]
26. Palestine, Gaza Strip,Beit Lahia Group B
Local inhabitants,
random population
sample, 3–18 years
N/a 5.6% (90/1600) Stool examination Not reported Agricultural region [45]
27. Brazil, Bahia Group A, C
AIDS Clinic patients,
HIV positive and
negative groups,
random
population sample
Developing
economy, 3
1.05%
(59/5608) Stool examination
Gastrointestinal
symptoms among
HIV positive
Study conducted from
1997 to 1999 [46]
28. Argentina (North) *** Group C Local patients at thehospital
Developing
economy, 3 29.4% (67/228) Stool examination Not reported [47]
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NO. Most Likely InfectiveSource
Climate
Classification Population Studied SES
S. stercoralis
Prevalence (%)
Type of
Detection
Symptoms
Diagnosed Comments/Details Reference
29. U.S. Group B, C, D Cancer treated patients Developedeconomy, 4
0.25%
(25/10000) Stool examination
Fever (28%),
gastrointestinal
symptoms (68%),
pruritic skin rash,
Cases between 1971
and 2003 22/25 are
US residents
[48]
30. Northeast Thailand Group A Local rural inhabitants Developingeconomy, 3
28.9% (96/332)
47.5% (57/120)
Stool examination
Serology Not reported
Study conducted
between
October–November
2000
[49]
31.
Africa (48%), Asia (34%),
Caribbean (20%), South
America (3%)
Group A, B, C
Immigrants from
endemic countries,
travelers, Hospital for
Tropical Diseases patients
Developing
economy,
1,2,3
53.1%
(102/192)
94.6%
(157/166)
Stool examination
Serology
Bowel upset,
gastrointestinal
symptoms,
skin symptoms
Study conducted
between 1991 and
2001, London
[50]
32. Bangladesh, Dhaka Group A, C Local inhabitants ofa slum
Developing
economy, 1
23.1% (34/147)
10.2% (15/147)
61.2% (90/147)
Stool examination
Stool examination
(agar plate
culture) Serology
Diarrhea (19%)
Study conducted from
November 2009 to
January 2010
[51]
33. Nigeria, llorin Group A
HIV clinics patients, HIV
seropositive and
seronegative patients
Developing
economy, 2 12.2% (22/180) Stool examination Not reported [52]
34. Southeastern Brazil,Uberlandia Group A, C
Elderly, randomly
selected from nursing
homes and
non-institutionalised
Developing
economy, 3 5% (10/200) Stool examination Asymptomatic [53]
35. Australia, Queensland,Doomadgee *** Group B, C
Children in aboriginal
communities
Developed
economy, 4 27.5% (92/334) Stool examination Not reported During the wet season [23]
36. Northern Cambodia Group A
Local inhabitants,
random
population sample
Developing
economy, 1
44.7%
(1071/2396) Stool examination Not reported
Farmers (48.5%),
pupils (33%) [54]
37. Kazakhstan *** Group D Adopted children, livedin orphanage
Economy in
transition, 3 42.8% (3/7) Serology Not reported Study in Belgium [22]
38. USSR,North Caucasus *** Group D
Local inhabitants,
random
population sample
Developing
economy, 2
0.77%
(89/11530) Stool examination Not reported [55]
39. Japan, Okinawa *** Group B Local hospital patients Developedeconomy, 4
3.4%
(113/3292)
Stool examination
(agar plate
culture)
Not reported
S. stercoralis is higher
in B. hominis infected,
the last is indicator for
poor hygiene
[56]
* Koppen climate classification major categories: Group A—tropical moist climate; Group B—subtropical, dry climate; Group C—subtropical, mediterranean, moist mid-latitude
climates with mild winters; Group D—continental, moist mid-latitude climates with cold winters; Group E—polar climate; Group H—highland climate; ** Country’s income level
categories: 1—low-income; 2—lower-middle-income; 3—upper-middle-income; 4—high-income; *** Strongyloidiasis cases in these countries are shown as a “star” sign on a map in
Figure 1.
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Figure 1. Countries with Strongyloides stercoralis cases (colored blue or marked as a “star” sign) on a
world map divided into tropical and subtropical zones.
2. Global Prevalence of Strongyloidiasis and Climate Classification
Table 1 summarizes th information available on infection prevalence, populati n studied, country
as the most likely infective source, climate and socio con mic status of the country, type of th infection
detection, presence of symptoms and the study reference details. The table indicates that all cas s
of str ngyloidiasis ccur in the following communities: po r communities, former war veter s,
i migrants and travel rs, immunocompromised population , or groups occupationally ex osed
to soil.
The climate classificati n sed in this review is the Koppen climate classification s stem, which
divides the world’s climate into six major climate groups each containing several subgroups [57].
Using the complete range of Koppen climate categories, about 80% of all the world areas falls into
either tropical or subtropical zones [57]. This justifies th lassification of strongyloidiasis as a “tropical”
or “subtropical” disease, but lacks any meaning or association. Based on the major Koppen climate
categories, the infection is still prevalent in other climate zones apart from tropical or subtropical ones
(Figure 1). Certain areas of countries with Strongyloides stercoralis cases are shown as a “star” sign on
the map.
Figure 1 presents a world map divided into tropical and subtropical zones with the
strongyloidiasis case countries/areas colored in blue. It can be seen that strongyloidiasis is highly
prevalent in subtropical and tropical regions representing mostly developing countries with low
socioeconomic status. Cases outside the tropical or subtropical areas correspond to more economically
developed countries, but socioeconomically depressed communities (e.g., the Appalachia region
population in the U.S., former USSR countries). This emphasizes that socioeconomic factors are more
important than climatic conditions in defining the disease. The remaining cases presented are in
risk groups of developed economy countries such as former war veterans, refugees, immigrants and
travelers, immunosuppressed people or current or ex-farmers and their families, also identified by
Schär et al. [24].
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3. Countries of Strongyloidiasis Prevalence and Socioeconomic Status
3.1. Socioeconomic Status of the Strongyloidiasis Case Communities in Subtropical and Tropical
Zones (Hyperendemic)
The socioeconomic status of the countries are presented in Table 1, based on their economy
status and the income using World Bank data and the United Nations “World’s Economic Situation and
Prospects 2016”report [58,59]. It is globally accepted that an area with S. stercoralis prevalence of more
than 5% is considered hyperendemic [60]. From Table 1 it can be seen that almost all the reported
countries are shown to be hyperendemic for strongyloidiasis, with exception of the Appalachia region
in the U.S., Okinawa in Japan and North Caucasus in the former USSR. The reported endemic areas
for strongyloidiasis (Southeast Asia, Africa, Central and South America) are mostly countries with
developing economies, as can be seen in Table 1. Socioeconomic inequalities result in poor sanitation
and hygienic conditions, which act as a triggering factor for the pathogen infection [17]. The lifecycle
of S. stercoralis and a mode of infection transmission justifies the notion that improper sanitation
conditions are risk factors for infection [3]. Increased urbanization processes happening in such
countries cause inappropriate living conditions for the population such as 5–6 people living in one
room and the use of one cubicle shower and a toilet [32]. It has been frequently shown that low
socioeconomic status communities present higher mortality and morbidity rates compared to higher
socioeconomic class population [61,62].
3.2. Socioeconomic Status of the Strongyloidiasis Case Communities in Temperate Zones
Apart from high prevalence strongyloidiasis cases detected in most of the subtropical and tropical
countries in the world, cases with strongyloidiasis prevalence were also shown in some continental
climate regions (Appalachia, North Caucasus, Kazakhstan). Although the study conducted in the
North Caucasus does not meet the current review’s criterion for the year of publication of papers,
it is still included as not many studies from that area are available. North Caucasus has a continental
climate and the study findings highlight that strongyloidiasis is not dependent only on climatic
conditions [55].
While moist and warm soil, enriched with nutrients are favourable conditions for the survival of
free-living S. stercoralis larvae with further potential to infect a human host, the factors influencing
direct or indirect development of infective filariform larvae (L3) are poorly understood [1,60]. Previous
reports have indicated that larvae cannot survive temperatures below 8 ˝C or above 40 ˝C [63].
However, studies have demonstrated S. stercoralis larvae surviving at lower temperatures infecting
a human [55]. Considering the parthenogenesis and autoinfection features of this nematode, the
likelihood of the larvae remaining and reproducing within the host is high. In conditions of inadequate
sanitary and hygiene environment there is then a high risk of rhabditiform larvae excreted in stools
passing to other human hosts.
As seen in Table 1, these regions belong to countries or a country with transitional or developed
economies with the strongyloidiasis cases identified only in disadvantaged communities [21,22,55].
For example, rural Appalachia regions in Kentucky, West Virginia, Georgia and Tennessee in the
United States are identified as areas with high infection prevalence among low socioeconomic status
populations [21,64]. The Strongyloides infection case reported in Kazakhstan children were adopted
children from orphanages, who probably were exposed to poor sanitary environments [22]. The study
in the North Caucasus reported different levels of strongyloidiasis prevalence (0.1%–1.4%) in different
areas with different temperatures (the lowest being 4 ˝C). Poor sanitary conditions were however
reported in almost all the communities studied [55]. These single Strongyloides infection cases occurred
in areas of continental climate, where the precipitation level is low and temperatures go below zero,
demonstrating that strongyloidiasis is not primarily influenced by climate conditions but rather
sanitary and hygiene factors.
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Australia is known to have tropical and subtropical climates, however, strongyloidiasis there is
frequently found among indigenous communities and not the general population [20,23]. Indigenous
communities (Aborigines and Torres Strait Islanders) are identified as of a low socioeconomic status
populations and are generally reported to live in poorer housing, sanitary and infrastructure conditions,
which results in numerous worse health outcomes compared with non-indigenous Australians [65].
3.3. Clinical Treatment of Strongyloidiasis and Infrastructure, Housing, and Environmental Health
Currently, anthelminthic drugs (albendazole, mebendazole, and ivermectin) and nemiticides
are used to treat the strongyloidiasis in humans [66]. Treatment of soil-transmitted helminthiasis is
difficult due to the development of resistance and facile reinfection from the environment. Among
soil-transmitted helminth infections, strongyloidiasis is the most challenging to treat and clinically
important because of a parasite’s rhabditiform larvae unique ability of autoinfection [2,13,26,32].
Moreover, parthenogenesis allows for a single female parasite remaining in a host to reproduce
reinfecting that person [1]. The drug treatment efficacy depends on number of factors including
an individual’s immune system status, co-infection with HTLV-1, history of drug use, and bowel
ileus [51,67–69]. Furthermore, monitoring treatment efficacy has some difficulties associated with the
low sensitivity of fecal examination [13]. Additionally, the drugs can cause adverse effects, including
liver disfunction, gastrointestinal symptoms (nausea, vomiting, loose stool, abdominal distension
or pain), chest tightness or pain, itching, fever, cough and wheezing, dizziness, and neurological
effects [27,28,70,71].
New anthelminthic drugs and nematicides have to be frequently introduced to the market due to
quick resistance development in nematodes and great toxicity they produce to humans [26]. Resistance
in nematodes to different drugs has been studied and demonstrated frequently in the veterinary field
in the last decades [72–74]. This suggests that human-infecting nematodes are also likely, at some stage
in the future, to become resistant to the available drugs. Indeed, studies on some drugs used against
human nematodes have already reported low drug treatment efficacy, calling for great attention and
warnings of possible resistance development [75,76]. Although it is more difficult to study and confirm
anthelminthic resistance in human parasites due to number of factors, the potential for resistance is
mostly overlooked and should be more carefully examined in drug treatment application [77].
It is well established that sanitary conditions, including housing and infrastructure, play the
most vital role in determining health outcomes [78,79]. Overcrowding, poor ventilation, bad living
conditions and inadequate sewerage systems create higher risks for infectious and parasitic diseases
such as skin infections, respiratory infections and diarrheal diseases [80]. Thus, environmental health
approaches such as ensuring better infrastructure and sanitation should be the primary approach to
controlling Strongyloides in the environment. Only this approach will provide the most effective way of
infection reduction.
Strongyloidiasis has been also reported in certain groups such as former war veterans, refugees,
immigrants and travelers, immunocompromised people and people occupationally exposed to soil
(Table 1). Poor sanitary and hygiene living conditions are common during times of war, which could
explain cases of strongyloidiasis in former war veterans [16,40]. The Okinawa Prefecture area of Japan
was reported to have a high prevalence of S. stercoralis infections during World War II, which decreased
to about 0.5%–1.5% after the war years. This was associated with improved sanitary conditions and
systematic monitoring for parasitic diseases after the war [81].
Studies of refugees and immigrants with high S. stercoralis infection prevalence have demonstrated
an association with inadequate sanitary and hygienic conditions in their home countries, including
lack of an access to shower and toilet facilities [4,8,19,31,33,36,38,41,50].
Individual health condition (immunosuppressed or immunocompromised status) is another risk
factor influencing the disease [5]. S. stercoralis is especially life-threatening to immunocompromised
people due to possible development of the disseminated disease form [5,8] which approaches a 90%
mortality rate [5,82]. The study by Zaha et al. [81] demonstrated that there was a high prevalence of
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S. stercoralis among Human T-Lymphotropic Virus type I (HTLV-1) positive patients (17.5%) compared
to HTLV-1 negative patients (6.7%). Schar et al. [24] found an association between strongyloidiasis and
HIV infection (OR: 2.17 BCI: 1.18–4.01) and alcoholism (OR: 6.69; BCI: 1.47–33.8). HTLV-1 and HIV
infections and alcoholism have been associated with poverty [61,83–85].
High prevalence of strongyloidiasis in subtropical South China has been reported by
Wang et al. [86]. While the cases reported are within subtropical areas, they are mostly associated with
the farming lifestyle in those regions and/or poor hygiene practices. The infection rates in these areas
are as high as 11%–14% [86]. The studies’ findings are not included in Table 1, as the original papers are
only available in Chinese. Similarly, studies in France and Spain [37,42,87] reported strongyloidiasis
cases in local current or ex-farmworkers and their family members who have never travelled to endemic
areas. While there is no available information on the income of the studied population, ingestion of
non-potable water and possible infection transmission to family members due to unhygienic behavior
is reported in one of the studies [42]. This might indicate either inappropriate living conditions due to
the depressed socioeconomic status in the area or population unawareness of proper hygienic and
sanitary standards. On the other hand, in another study by Roman-Sanchez et al. [37] the assessed area
(Gandia, Valencia), is reported to have the highest per capita income compared to other European Union
regions, adequate hygiene-sanitary conditions and high prevalence of the strongyloidiasis. Whether
the use of a more sensitive detection method, the agar-plate culture technique, compared to other
studies impacted on this result cannot be known until several studies using the same detection tests
are conducted. It can, however, be concluded that occupation is likely to contribute to acquiring the
infection in this case.
Currently, it is estimated that between 30–100 million people are infected by Strongyloides
worldwide [2,88]. There is however a general consensus amongst the scientific community that the
prevalence is underestimated due to inadequate diagnostic techniques [88], and the lack of sensitivity in
tests for S. stercoralis and the similarity of its symptoms to other diseases result in great underestimation
of the infection and 300 million people infected globally is probably a more accurate estimate [47,89].
Misclassification of the disease may also be contributing to the underestimation of its prevalence.
Diagnostic test methods are presented in Table 1 for completeness.
4. Conclusions
It is well established that strongyloidiasis is mainly restricted to tropical and subtropical areas
throughout the world. However, within these regions, exposure to infection with the helminth is
strongly associated with poor sanitary and living conditions. Thus, immigrants, refugees, travelers,
war veterans, immunocompromised and occupationally soil-exposed groups—and their family
members—are at especially high risk of strongyloidiasis. This review emphasizes that strongyloidiasis
is a disease of disadvantage, and suggests that control measures to prevent the infection should focus
as much, or more, on changing the environmental conditions that increase overall risks of the disease,
as on the medical treatment of infected persons, especially since the latter is ineffective in preventing
reinfection and has the potential for the development of drug resistance.
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